CD4 and renal cell carcinoma: Based on our previous studies documenting Type-1 tumor-specific CD4+ T cell dysfunction in the peripheral blood of patients with melanoma or RCC (17, 18, 22), the current studies were developed to provide further insights into potential mechanisms that may underlie such deficiency in the advanced disease setting.